This significant achievement follows an extensive evaluation period during which the hospital has, assessed the vetIQure™ and TSE treatments. This permanent installation and order is a recognition of its quality, value and benefits.

Under the leadership of Nanna Åkerlund Denneberg, AniCura Jönköping has treated various types of oncological patients and conducted case-series evaluations of the vetIQure™ TSE system. An interview with Nanna talking about her experiences with TSE so far was published in the journal Veterinärmagazinet (https://www.veterinarmagazinet.se/), in July 2024. The interview will be attached to this press release (in Swedish).

"We are pleased to continue building on our relationship with AniCura and the Mars Petcare family, and we hope that this collaboration will expand to other AniCura and Mars Petcare owned hospitals and clinics in Europe and the USA," says Mohan Frick, CEO of Scandinavian ChemoTech and Vetiqure. "This order is a testament to hard work and confirms the innovative solutions we have developed to meet the needs of the veterinary and animal care industry. We look forward to a continued successful partnership that will drive growth and create new opportunities for both companies."

AniCura Jönköping, known for its commitment to providing top-quality veterinary oncological care, has recognized the potential of permanently integrating TSE into its daily operations, enhancing its ability to deliver high-quality oncological care to pets and their owners.

As Vetiqure AB continues its journey and embarks on a new chapter, our focus remains on providing world-class innovation. This also marks our ongoing commitment to improving methods and contributing to the establishment of new standards in veterinary oncology and tumour care.

About AniCura:

AniCura is one of Europe's leading providers of high-quality veterinary care for pets, with clinics in 300 locations across Europe. Offering a wide range of medical and surgical services, AniCura ensures peace of mind for pet owners through high availability and patient safety. With 6,000 employees, they care for more than 3 million patients annually. AniCura is also a recognized training and referral body. Since 2018, AniCura Group has been a wholly owned subsidiary of Mars Petcare.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-09-2024 09:13 CET.